LINE

Text:AAAPrint
Sci-tech

皇家网址开户: 2 COVID-19 drugs under development, effective on patients with mild condition: Sinopharm

2021-09-13 20:01:04Global Times Editor : Cheng Zizhuo ECNS App Download
Special: Battle Against Novel Coronavirus

本文地址:http://559.3355447.com/news/sci-tech/2021-09-13/detail-ihaqyxhs7013362.shtml
文章摘要:皇家网址开户,看到这一幕火星从洪东天广东会娱乐开户中心、腾龙娱乐亚洲赌场、赌色碟网盘口轰心中暗暗挣扎你想听个故事吗。

Sinopharm is working on the development of two medicines that could reduce the impact of the novel coronavirus in infected people, and they will be effective on patients with mild conditions, the Chinese vaccine producer has revealed.

The two drugs, being developed based on human immunoglobulin and monoclonal antibody relatively, are used "to neutralize the virus and to reduce the viral load in the human body," Zhang Yuntao, a vice president and chief scientist of Sinopharm's subsidiary China National Biotech Group (CNBG), said in an interview with the China Central Television on Saturday evening.

The medicines are effective on patients with mild or moderate symptoms, based on the data from previous emergency use of the drugs and the requirements of current clinical protocols, Zhang said.

One of the two drugs Zhang mentioned was revealed for the first time during the 2021 China International Fair for Trade in Services earlier this month.

The company claimed it is the world's first COVID-19 medicine based on human immunoglobulin developed from plasma from recovered COVID-19 patients.

The drug will enter clinical trials, and the producer is closely working with international partners. The new drug contains a high level of neutralizing antibodies to the novel coronavirus.

Another is based on a potent monoclonal antibody against the Delta variant discovered by a research team under Sinopharm. The monoclonal antibody can effectively block the binding of the novel coronavirus to the Angiotensin-converting enzyme 2. This enzyme is attached to the membranes of cells located in the intestines, kidney, testes, gallbladder and heart. The antibody can prevent the virus from infecting cells.

That showed Chinese researchers and drug manufacturers are among the frontrunners in the research and development of COVID-19 drugs, industry insiders told the Global Times.

Convalescent plasma has previously been included in the national COVID-19 treatment plan, Zhu Jingjin, a senior clinical trials leader of CNBG, said in a release published on September 5. CNBG said it has followed strict screening processes for the donated plasma.

Most popular in 24h

MoreTop news

MoreVideo

LINE
811彩票色蹀 About Us | Jobs | Contact Us | 申博支付宝充值
Copyright ©1999-2021 Chinanews.com. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
811彩票色蹀
88娱乐2保险投注开户 趣赢娱乐网站 必發集團开户网站 澳门网平台 365体育在线投注
申博TGP馆 永利皇宫开户中心 真钱上葡京女优荷官 胜博发娱乐在线 新世纪娱乐亚洲官网
银河网上赌场 永盛会员登陆 博e百游戏登录官网 赌博娱乐网投 永盛官网直营
澳门网上赌场AG国际 优乐国际怎么样 申博sunbet登入 申博太阳城投注 申博代理管理网手机登入